Steven Duncan

Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

National Heart, Lung, and Blood Institute · U01

Contact PI · $3.8M · University of Alabama at Birmingham

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease

National Heart, Lung, and Blood Institute · P01

Project lead · $1.6M · Tulane University of Louisiana

Rituximab Therapy in Patients with IPF

National Heart, Lung, and Blood Institute · R01

Contact PI · $3.4M · University of Alabama at Birmingham

Impact of CCR5 Inhibition on Sarcoid Immunophenotypes

National Heart, Lung, and Blood Institute · U01

PI · $443.8K · University of Pittsburgh at Pittsburgh

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

Principal investigator · Not yet recruiting · Phase 2

University of Alabama at Birmingham

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

Principal investigator · Completed · Phase 2

University of Alabama at Birmingham

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

Principal investigator · Completed · Phase 2

University of Alabama at Birmingham

A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

Principal investigator · Withdrawn · Phase 2

University of Pittsburgh